Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CSF2 knockdown alters gene expression profiles in BCPAP papillary thyroid carcinoma cells

ABSTRACT: This study investigates the transcriptomic changes in BCPAP papillary thyroid carcinoma (PTC) cells following CSF2 knockdown using Affymetrix PrimeView Human Gene Expression Array. CSF2 knockdown was achieved via shRNA, with non-targeting shRNA as control. Three biological replicates per group were analyzed. Results show that CSF2 regulates genes involved in cell proliferation, invasion, and metastasis, particularly through the STAT3-CXCL5-WNT/beta-catenin axis. Our findings provide insights into CSF2 as a potential therapeutic target in PTC progression.

ORGANISM(S): Homo sapiens

PROVIDER: GSE330622 | GEO | 2026/05/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Human Papillary thyroid cancer cell line, BCPAP control vs. miR-146b-5p mimic transfected

Project description:Transcriptional profiling of human papillary thyroid cancer cells comparing control untreated BCPAP cells with BCPAP cells transfected with miR-145b-5p mimic. Two-condition experiment, BCPAP cells vs. miR-146b-5p transfexted BCPAP cells. Biological replicates: 1 control sample, 1 transfected sample.

2015-12-17 | E-GEOD-76050 | biostudies-arrayexpress

Gene expression profiles in BCPAP cells treated with BRAF inhibitors

Project description:We performed gene expression profiling in the human papillary thyroid carcinoma (PTC) derived cell line BCPAP harboring BRAFV600E mutation following the treatment with BRAF selective inhibitors.

2021-07-13 | GSE171483 | GEO

Human Papillary thyroid cancer cell line, BCPAP control vs. miR-146b-5p mimic transfected

Project description:Transcriptional profiling of human papillary thyroid cancer cells comparing control untreated BCPAP cells with BCPAP cells transfected with miR-145b-5p mimic.

2015-12-17 | GSE76050 | GEO

Expression data of BCPAP cells with LRRC34 knockdown

Project description:Expression data of BCPAP cells with LRRC34 knockdown

| PRJNA556150 | ENA

Expression data of BCPAP cells with EPB41L4A knockdown

Project description:Expression data of BCPAP cells with EPB41L4A knockdown

| PRJNA624365 | ENA

Validation of the Personalized Gene Therapy by stably transfection of PANK2 in the papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines

Project description:An ideal cancer gene therapy would selectively destroy the cancer cells without affecting much the healthy tissue. This would be possible if and only if the cancer and normal cells of the tumor are governed by distinct gene master regulators (GMRs). Logic dictates that, while being strongly protected by the homeostatic mechanisms, expression of a GMR governs the phenotype by modulating major functional pathways through controlling the expression of the involved genes. We determined the GMRs of the standard papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines. The hierarchy of the known biomarkers was established based on their gene commanding height (GCH), an original measure combining the expression control and coordination with expression of other genes. We found that the sets of the GMRs are largely different in the two thyroid cancer cell lines, indicatibg that each type of thyroid cancer needs a different gene-targeting therapy. In this experiment, we determined the transcriptomic effects of the stable transfection of PANK2 gene In the papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines. PANK2 was selected because it has significantly different GCHs in the two cell lines: 44.64 in BCPAP and 3.61 in 8505C. The significantly more up- and down-regulated genes in the transfected BCPAP than in the transfected 8505C cells compared to their untransfected counterparts validated the theory and indicated the usefulness of our personalized gene therapy approach.

2017-03-25 | GSE97030 | GEO

Validation of the Personalized Gene Therapy by stably transfection of DDX19B in the papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines

Project description:An ideal cancer gene therapy would selectively destroy the cancer cells without affecting much the healthy tissue. This would be possible if and only if the cancer and normal cells of the tumor are governed by distinct gene master regulators (GMRs). Logic dictates that, while being strongly protected by the homeostatic mechanisms, expression of a GMR governs the phenotype by modulating major functional pathways through controlling the expression of the involved genes. We determined the GMRs of the standard papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines. The hierarchy of the known biomarkers was established based on their gene commanding height (GCH), an original measure combining the expression control and coordination with expression of other genes. We found that the sets of the GMRs are largely different in the two thyroid cancer cell lines, indicatibg that each type of thyroid cancer needs a different gene-targeting therapy. In this experiment, we determined the transcriptomic effects of the stable transfection of DDX19B gene In the papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines. DDX19B was selected because it has significantly different GCHs in the two cell lines: 1.64 in BCPAP and 6.03 in 8505C. The significantly more up- and down-regulated genes in the transfected 8505C than in the transfected BCPAP cells compared to their untransfected counterparts validated the theory and indicated the usefulness of our personalized gene therapy approach.

2017-03-25 | GSE97028 | GEO

Validation of the Personalized Gene Therapy by stably transfection of UBALD1 in the papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines

Project description:An ideal cancer gene therapy would selectively destroy the cancer cells without affecting much the healthy tissue. This would be possible if and only if the cancer and normal cells of the tumor are governed by distinct gene master regulators (GMRs). Logic dictates that, while being strongly protected by the homeostatic mechanisms, expression of a GMR governs the phenotype by modulating major functional pathways through controlling the expression of the involved genes. We determined the GMRs of the standard papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines. The hierarchy of the known biomarkers was established based on their gene commanding height (GCH), an original measure combining the expression control and coordination with expression of other genes. We found that the sets of the GMRs are largely different in the two thyroid cancer cell lines, indicatibg that each type of thyroid cancer needs a different gene-targeting therapy. In this experiment, we determined the transcriptomic effects of the stable transfection of UBALD1 gene in the BCPAP and 8505C thyroid cancer cell lines. UBALD1 was selected because it has significantly different GCHs in the two cell lines: 10.31 in 8505C and 1.12 in BCPAP. The significantly more up- and down-regulated genes in the transfected 8505C cells than in the transfected BCPAP cells compared to their untransfected counterparts validated the theory and indicated the usefulness of our personalized gene therapy approach.

2017-04-06 | GSE97427 | GEO

Validation of the Personalized Gene Therapy by stably transfection of NEMP1 (TMEM194A) in the papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines

Project description:An ideal cancer gene therapy would selectively destroy the cancer cells without affecting much the healthy tissue. This would be possible if and only if the cancer and normal cells of the tumor are governed by distinct gene master regulators (GMRs). Logic dictates that, while being strongly protected by the homeostatic mechanisms, expression of a GMR governs the phenotype by modulating major functional pathways through controlling the expression of the involved genes. We determined the GMRs of the standard papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines. The hierarchy of the known biomarkers was established based on their gene commanding height (GCH), an original measure combining the expression control and coordination with expression of other genes. We found that the sets of the GMRs are largely different in the two thyroid cancer cell lines, indicatibg that each type of thyroid cancer needs a different gene-targeting therapy. In this experiment, we determined the transcriptomic effects of the stable transfection of NEMP1 (TMEM194A) gene encoding a nuclear envelope protein in the papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines. NEMP1 was selected because it has significantly different GCHs in the two cell lines: 5.95 in BCPAP and 0.40 in 8505C. The significantly more up- and down-regulated genes in the transfected BCPAP than in the transfected 8505C cells compared to their untransfected counterparts validated the theory and indicated the usefulness of our personalized gene therapy approach.

2017-03-25 | GSE97031 | GEO

Chicken CSF2 and IL-4-, and CSF2-Dependent Bone Marrow Cultures

Project description:Chicken CSF2 and IL-4-, and CSF2-Dependent Bone Marrow Cultures Represent Macrophages

| PRJEB56177 | ENA